Merck continues to lay the groundwork for its upcoming introductionof Fosamax, a new drug for the treatment of osteoporosis. TheWest Point, PA, drug company has entered into an agreement withCompuMed to license that company's OsteoGram test for
Merck continues to lay the groundwork for its upcoming introductionof Fosamax, a new drug for the treatment of osteoporosis. TheWest Point, PA, drug company has entered into an agreement withCompuMed to license that company's OsteoGram test for measuringbone density.
Merck is close to receiving Food and Drug Administration approvalfor Fosamax, which is expected to give a lift to the bone densitometrymarket. In June the company signed agreements with Lunar and Hologicto provide financial assistance for physicians who wish to purchasedensitometry scanners from those firms (SCAN 7/6/95).
The agreement with CompuMed of Manhattan Beach, CA, complementsthose deals by extending Merck's influence over another methodof measuring bone density. OsteoGram enables physicians to usestandard x-ray equipment to detect low bone mass using a techniquecalled radiographic absorptiometry.
Under the terms of the deal, Merck will receive exclusive worldwiderights to OsteoGram in exchange for paying licensing fees androyalties to CompuMed on all OsteoGram tests performed over afive-year period.
Merck will also operate on a nonprofit basis OsteoGram AnalysisCenter, which performs computer analyses as part of the OsteoGramtest. The center will be operated by Merck's nonprofit Bone MeasurementInstitute.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.